Arcus Biosciences Ownership
| RCUS Stock | USD 10.26 0.12 1.18% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 91.1 M | Current Value 91.4 M | Avarage Shares Outstanding 57 M | Quarterly Volatility 21.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Arcus |
Arcus Stock Ownership Analysis
About 84.0% of the company shares are owned by institutional investors. The book value of Arcus Biosciences was at this time reported as 6.18. The company recorded a loss per share of 3.16. Arcus Biosciences had not issued any dividends in recent years. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people. To find out more about Arcus Biosciences contact Terry Rosen at 510 694 6200 or learn more at https://www.arcusbio.com.Besides selling stocks to institutional investors, Arcus Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Arcus Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Arcus Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Arcus Biosciences Quarterly Liabilities And Stockholders Equity |
|
Arcus Biosciences Insider Trades History
About 6.0% of Arcus Biosciences are currently held by insiders. Unlike Arcus Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Arcus Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Arcus Biosciences' insider trades
Arcus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arcus Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcus Biosciences backward and forwards among themselves. Arcus Biosciences' institutional investor refers to the entity that pools money to purchase Arcus Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parkman Healthcare Partners Llc | 2024-12-31 | 1.3 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Millennium Management Llc | 2024-12-31 | 924.4 K | Decheng Capital Llc | 2024-12-31 | 808.8 K | Braidwell Lp | 2024-12-31 | 802.1 K | Charles Schwab Investment Management Inc | 2024-12-31 | 579.6 K | Suvretta Capital Management, Llc | 2024-12-31 | 576.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 549.9 K | Northern Trust Corp | 2024-12-31 | 532.1 K | Blackrock Inc | 2024-12-31 | 9.7 M | Vanguard Group Inc | 2024-12-31 | 5.4 M |
Arcus Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arcus Biosciences Outstanding Bonds
Arcus Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arcus Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arcus bonds can be classified according to their maturity, which is the date when Arcus Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US03969YAA64 Corp BondUS03969YAA64 | View | |
| US03969YAB48 Corp BondUS03969YAB48 | View | |
| AMPBEV 6 15 JUN 27 Corp BondUS03969YAC21 | View | |
| US039653AA89 Corp BondUS039653AA89 | View | |
| Ardagh Holdings USA Corp BondUS03969AAP57 | View | |
| Ardagh Holdings USA Corp BondUS03969AAN00 | View | |
| Ardagh Packaging Finance Corp BondUS03969AAR14 | View |
Arcus Biosciences Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 11th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.